Brimonidine in Rosacea

Not Applicable

• Conditions: Rosacea
• Interventions: Other: treatment

• Registration Number: NCT05401422
• Lead Sponsor: Cairo University

Brief Summary

Rosacea is a chronic and relapsing inflammatory cutaneous disorder with highly variable prevalence worldwide.

Detailed Description

In our study, we will compare the safety, efficacy, and adverse effects of low-dose oral doxycycline alone versus combined with pulsed dye laser or topical brimonidine in treating erythematotelangiectatic rosacea in an attempt to build a treatment strategy in a disease with complex pathogenesis.

Study Timeline

• Study First Submitted: 2022-05-20
• Study Start: 2022-05-25
• Status Verified: 2022-06
• Study First Submitted QC: 2022-06-01
• Last Update Submitted: 2022-06-01
• Study First Posted: 2022-06-02
• Last Update Posted: 2022-06-02
• Primary Completion: 2022-09-15
• Study Completion: 2022-09-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Patient with current erythematotelangiectatic rosacea

Exclusion Criteria

• Pregnant females. 2-Patients on systemic steroids. 3-Patients complaining of other dermatological disorders mainly photosensitive cutaneous disorder.

4- Patients receiving any systemic treatment including retinoids for the previous 1 month or any topical treatment for the previous 2 weeks or any laser sessions for the previous 3months for erythematotelangiectatic rosacea at least.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Doxycycline	treatment	Drug
Pulsed dye laser	treatment	Laser
Brimonidine gel 0.33%	treatment	Topical drug

Primary Outcome Measures

Name	Time	Method
Clinical erythema assessment scale	3 months	clinical scale

Secondary Outcome Measures

Name	Time	Method
Thickness of capillaries by dermoscope	3 months	Assessment